Adam S. Grossman is a seasoned executive who currently serves as Director, President, Chief Executive Officer, and Interim Chief Financial Officer at ADMA Biologics Inc., a biopharmaceutical company focused on developing and commercializing specialty plasma-based biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. With over two decades of experience in the biopharmaceutical industry, Grossman has been instrumental in guiding ADMA Biologics through various stages of growth and development. Before joining ADMA Biologics, Grossman held several leadership positions at other biopharmaceutical companies, where he gained extensive experience in strategic planning, business development, and operational management. His expertise in these areas has been crucial in driving ADMA Biologics' success, particularly in the development and commercialization of their flagship products, BIVIGAM and ASCENIV. Under Grossman's leadership, ADMA Biologics has made significant strides in expanding its product portfolio and strengthening its position in the specialty plasma-based biologics market. As Director, President, and CEO, Grossman is responsible for overseeing the overall strategic direction and operations of ADMA Biologics. In his additional role as Interim CFO, he also manages the company's financial strategy and ensures the effective allocation of resources to support its growth initiatives. Grossman's leadership has been pivotal in navigating the challenges of the biopharmaceutical industry, and his vision for the company's future continues to drive ADMA Biologics towards its goal of improving the lives of patients with immune deficiencies and other serious health conditions.